RenovoRx Receives First Japanese Patent Notice of Allowance for RenovoCath Device

RenovoRx has received its first Notice of Allowance for a Japanese patent related to its RenovoCath® device, which is designed for targeted, localized drug delivery through the vasa vasorum. The announcement marks a significant milestone in the company’s efforts to expand intellectual property protection for its proprietary technology on an international scale.

The RenovoCath® device enables precise delivery of therapeutic agents directly to affected tissues via the blood vessels that supply them, known as the vasa vasorum. This approach aims to enhance treatment efficacy while minimizing systemic exposure. The Notice of Allowance from Japan’s patent office represents a key step toward securing full patent rights in the region. This development follows similar approvals in other jurisdictions and reflects ongoing efforts by RenovoRx to protect and commercialize its innovative medical technologies globally.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI